Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Elicio Therapeutics, Inc. - Common Stock
(NQ:
ELTX
)
4.880
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Elicio Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
December 12, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
December 03, 2024
Phase 2 randomized study of ELI-002 enrolled 135 patients; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 13, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
November 07, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
October 31, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
October 16, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
September 17, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
September 13, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
August 12, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
June 28, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Proposed Public Offering
June 27, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
June 27, 2024
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 05, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
January 25, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
January 17, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
January 16, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
January 11, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
January 09, 2024
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
December 22, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 09, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
November 03, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
October 11, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
September 27, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
September 07, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
September 05, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
August 28, 2023
From
Elicio Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.